India's Covaxin, the homegrown government-backed vaccine, has an efficacy rate of 81%, preliminary data from its phase 3 trial shows. India's regulators gave the vaccine an emergency approval in January while the third phase of the trial was still under way, sparking scepticism and questions from e...